Literature DB >> 2104790

Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

T Andersson1, C Cederberg, G Edvardsson, A Heggelund, P Lundborg.   

Abstract

The effect of omeprazole treatment on diazepam plasma levels was studied in four slow and six rapid metabolizers of omeprazole. Single intravenous doses of diazepam (0.1 mg/kg) were administered after 1 week of oral treatment with omeprazole (20 mg) and placebo. This was a double-blind crossover study with randomized placebo and omeprazole treatments. Blood was collected up to 120 hours after diazepam dosing (still during one-daily omeprazole and placebo administration) for measurement of diazepam and its major metabolite desmethyldiazepam. The slow metabolizers of omeprazole also metabolized diazepam slowly, exhibiting only half the diazepam plasma clearance of the others. The mean clearance of diazepam was decreased 26% after omeprazole in the rapid metabolizers, whereas the slow group showed no apparent interaction. The mean plasma concentrations of desmethyldiazepam showed a more rapid formation in the rapid compared with the slow metabolizers, which is a logical consequence of the rate of diazepam metabolism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104790     DOI: 10.1038/clpt.1990.12

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  50 in total

1.  Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol.

Authors:  T Andersson; P Lundborg; C G Regårdh
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.

Authors:  P A Soons; G van den Berg; M Danhof; P van Brummelen; J B Jansen; C B Lamers; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

5.  S-mephenytoin 4-hydroxylation in older Americans.

Authors:  B G Pollock; J M Perel; M Kirshner; L P Altieri; A L Yeager; C F Reynolds
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects.

Authors:  M Hassan-Alin; T Andersson; M Niazi; K Röhss
Journal:  Eur J Clin Pharmacol       Date:  2004-12-01       Impact factor: 2.953

Review 7.  Single-isomer drugs: true therapeutic advances.

Authors:  Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

10.  Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects.

Authors:  M A Pue; J Laroche; I Meineke; C de Mey
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.